Nath Bio-Genes (India) Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nath Bio-Genes (India) Limited generated cash of $745,937,000, which is more than the previous year. Cash used in financing activities reached the amount of -$77,780,000 last year. Net change in cash is therefore $394,147,000.
Cash Flow
| 2016 | -141.67M | -169.22M | 307.42M |
|---|---|---|---|
| 2018 | -469.83M | -40.70M | 898.65M |
| 2020 | 94.74M | -144.37M | 55.63M |
| 2021 | 11.12M | -102.82M | 164.00M |
| 2023 | 383.66M | -28.84M | -16.68M |
| 2024 | 745.93M | -274.01M | -77.78M |
NATHBIOGEN.NS Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 379.95M | 41.80M | 219.84M | 213.79M | 58.46M | 15.72M |
Operating activities | ||||||
Net income | 415.64M | 361.64M | 567.51M | 485.08M | 300.54M | 152.34M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 32.61M | 30.12M | 28.15M | 14.52M | 9.50M | 39.04M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 27.64M | -118.82M | -20.58M | 13.54M | -296.22M | -4.35M |
Inventories | -224.62M | 124.96M | -219.91M | -489.51M | 66.93M | -237.04M |
Accounts payable | 155.60M | -150.46M | -229.72M | 180.04M | -77.53M | -36.07M |
Cash generated by operating activities | 745.93M | 383.66M | 11.12M | 94.74M | -469.83M | -141.67M |
Investing activities | ||||||
Purchases Of Investments | -9.98M | -2K | -502.4K | -2.4K | -2.4K | 0 |
Investments In Property Plant And Equipment | -267.75M | -25.48M | -115.98M | -162.03M | -48.58M | -216.17M |
Acquisitions Net | 0 | 471K | 1.52M | 4.64M | 2.89M | 444.30K |
Cash generated by investing activities | -274.01M | -28.84M | -102.82M | -144.37M | -40.70M | -169.22M |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 1.36B | 0 |
Payments for dividends | -38.00M | -38.00M | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 24.23M | -2.61M | -252.20M | -2.05M | -197.56M | 140.97M |
Cash used in financing activities | -77.78M | -16.68M | 164.00M | 55.63M | 898.65M | 307.42M |
Net Change In Cash | 394.14M | 338.14M | 72.31M | 6.00M | 388.11M | -3.47M |
Cash at end of period | 774.09M | 379.95M | 292.16M | 219.79M | 446.58M | 12.24M |
| Data source | Data source | Data source | Data source | Data source | Data source |